Trials / Completed
CompletedNCT01128686
Lamivudine(LAM) Good Responder Study
A Retrospective Cohort Study to Evaluate the Rate of Good Responses to Lamivudine (LAM) Treatment in naïve Chronic Hepatitis B (CHB) Patients With Certain Pre-treatment Characteristics
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1 (actual)
- Sponsor
- ViiV Healthcare · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is to evaluate the proportion of subjects who show good responses to LAM treatment in Korea.
Detailed description
This is to evaluate the proportion of subjects who show good responses to LAM treatment such as HBV DNA negativity, HBV DNA less than 4 log, no resistant mutation, HBeAg seroconversion and normalization of ALT in naïve CHB patients with certain pre-treatment characteristics, i.e. HBV DNA less than 9log copies per ml and ALT more than 2 times ULN in HBeAg positive subjects, HBV DNA less than 7log copies per ml and elevated ALT in HBeAg negative subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention | This study is retrospective chart review |
Timeline
- Start date
- 2010-08-01
- Primary completion
- 2011-06-01
- Completion
- 2011-06-01
- First posted
- 2010-05-24
- Last updated
- 2016-09-13
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01128686. Inclusion in this directory is not an endorsement.